S
troke is the third most frequent cause of death in the United States and is the leading cause of permanent disability. 1 Revascularization of severely atherosclerotic carotid arteries has been shown to be safe and effective in stroke prevention. [2] [3] [4] [5] Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are 2 alternative methods of revascularization and have been compared in small, randomized clinical trials. 6 -10 Although randomized trials provide the most scientifically valid comparisons between treatments, they do not reflect the diversity of patients or technical proficiency seen in broad contemporary clinical practice.
Clinical Perspective on p 94
Two major prospective registries have been developed to gather long-term, clinically enriched outcomes data in patients undergoing CEA and CAS. These registries are the Carotid Artery Revascularization and Endarterectomy (CARE) Registry (established by the American College of Cardiology [ACC] in partnership with several other organizations) and the Society for Vascular Surgery (SVS) Vascular Registry. 11 Using data from these prospective registries, some researchers have proposed and undertaken analyses aimed at comparing the clinical effectiveness of CAS and CEA. 12 However, for any comparisons to be valid, sufficient commonality must exist between the clinical characteristics of individuals referred for CAS and those undergoing CEA. Using data from the CARE registry, we sought to rigorously compare the clinical characteristics of patients referred for CAS and CEA as a foundation for understanding the potential opportunities and challenges for using real-world, observational data to test the comparative effectiveness of these 2 alternative treatments.
Methods

Registry
The CARE registry is a multispecialty society effort initiated by 7 organizations, the ACC, the Society for Cardiovascular Angiography and Interventions (SCAI), the Society of Interventional Radiology (SIR), the American Academy of Neurology, the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the Society for Vascular Medicine (SVM). Organization and design details have been published previously. 11 Currently, the CARE registry is operated by the National Cardiovascular Data Registry (NCDR). Similar to other NCDR registries, CARE is a voluntary, hospital-based, prospective, clinical procedure registry. There are standard data definitions and collection protocols, a data dictionary, and uniform collection tools. Procedural data on both CAS and CEA are collected by participating hospitals and submitted to a central data warehouse at NCDR. Independent 30-day neurology examinations are mandated for all patients. Quality control checks are performed initially by the warehouse, and unacceptable data are returned to the participant for correction and resubmission. Once acceptable, data are harvested quarterly into the dataset. These data harvests are then transmitted to the analysis center at Saint Luke's Mid-America Heart Institute, an independent analytic facility.
Patients
We examined registry data on 12 701 patients undergoing CAS or CEA procedures from January 1, 2005, through October 10, 2009. The primary objective of this descriptive analysis was to compare and contrast the clinical and sociodemographic characteristics of patients referred for CAS with those referred for CEA. All available registry patients were included in the analysis.
Statistical Analysis
Initial analysis included an unadjusted comparison of 44 clinical and sociodemographic characteristics of patients undergoing CAS and those referred for CEA. Categorical variables were compared using 2 tests and are presented as percentages. Continuous variables were compared using ANOVA and are presented as meanϮSD. To define patient characteristics independently associated with referral for CAS versus CEA, nonparsimonious multivariable logistic regression analysis for the probability of undergoing CAS was performed.
By creating a propensity score for CAS, we followed a wellvalidated statistical method designed to balance a large number of potential confounders equally across 2 observational cohorts of patients. [13] [14] [15] The propensity score for an individual is defined as the conditional probability of being treated (in this case referred for CAS) given the individual's covariates or characteristics. Once derived, many strategies can be employed to leverage the propensity score for comparative effectiveness research, including matching, stratification, and adjustment. 14 However, all of these methods presume that the propensity score can adequately balance the important clinical variables associated with outcomes. Stratification of propensity to be treated with CAS, by quintile, was used to retain all patients in the cohort and to provide the most accurate representation of patients referred for the 2 procedures in "real-world" clinical practice. To examine the ability of the propensity score to balance the sociodemographic and clinical characteristics of patients undergoing CAS or CEA, we compared the overall standardized differences in clinical covariates after propensity score stratification by quintile and described the proportion of CAS and CEA patients included within each propensity score quintile. We also examined the standardized differences within each quintile as well as the pooled standardized differences across all quintiles. The standardized difference is 100 times the absolute difference in sample means divided by an estimate of the pooled standard deviation of the variable. Thus, it represents the difference in means between the 2 groups in units of standard deviation. Generally, a standardized difference greater than 10% represents a meaningful imbalance between groups.
For patient characteristics to confound a comparative effectiveness analysis, they must be associated both with treatment and outcomes. To evaluate this association, we also assessed the raw, unadjusted 30-day mortality across quintiles. Statistical significance was defined as PՅ0.05. Mortality by quintile was then tested using the Cochran-Armitage test for trend. All statistical analyses were performed by the Saint Luke's Mid America Heart Institute Department of Biostatistics using SAS Version 9.2 (SAS Institute, Cary, NC).
Results
Population Characteristics
Among the 12 701 patients treated for advanced carotid artery disease within the CARE registry, 8069 were referred for CAS and 4632 were treated with CEA. The clinical characteristics among 44 different patient-level variables are shown in the Table. Patients referred for CAS were more likely to be nonwhite, to have multiple medical comorbidities, including dialysis, previous neck radiation or surgery, valve disease, prior carotid revascularization procedures, and neurological events.
Patient Characteristics Independently Associated With CAS
After multivariable analysis, 25 covariates were found to be significant predictors of referral for CAS, as shown in Figure  1 . Independent positive predictors of CAS referral include older age, peripheral arterial disease, target lesion symptomaticity within the past 6 months, chronic lung disease, current dialysis, advanced New York Heart Association (NYHA) and Canadian Cardiovascular Society (CCS) class, ischemic heart disease, congestive heart failure, moderate or severe aortic stenosis, prior neck surgery, contralateral carotid artery occlusion, absence of medical insurance, acute evolving stroke, tracheostomy, spontaneous carotid dissection, previous neck radiation, restenosis of prior CAS, prior CAS, fibromuscular dysplasia of the carotid artery, and restenosis of prior CEA. The independent negative predictors for referral for CAS include white race, plans for major surgery within the next 8 weeks, prior CEA in the contralateral carotid artery, and being a current smoker.
Distribution of the Population by Propensity to Undergo CAS
Propensity scores range from 0 to 1, reflecting a 0% to 100% probability of being treated with CAS as opposed to CEA. The distributions of propensity scores by treatment modality are shown in Figure 2 . For patients referred for CEA, the mean propensity score was 0.49 and the median score was 0.47, with an interquartile range of 0.37 to 0.60. For patients referred for CAS, the mean and median propensity score was 0.71, with an interquartile range of 0.54 to 0.91 (c-statisticϭ0.78).
To better demonstrate the overlap between treatment groups, the distribution of propensity scores by quintiles of propensity to undergo CAS are shown in Figure 3 . As evidenced by the figure, only 14% of the patients in the upper 2 quintiles were treated with CEA, whereas 86% underwent CAS. Propensity scoring and stratification by quintile failed to balance 7 covariates across all quintiles (prior CAS, prior CEA, prior myocardial infarction, increased angina burden, ischemic heart disease, CAS restenosis, and CEA restenosis) when rounded to one significant digit (see Table in the supplemental material). The most striking imbalances in propensity scores occurred in the 4th and 5th quintiles (Figure 4 ). In the 4th quintile, 8 covariates had standardized differences of Ն10% and 14 variables were not balanced in the 5th quintile. In all, 16 different covariates maintained standardized differences of Ն10% in quintiles 4 and 5.
Outcomes of Carotid Revascularization by Propensity to Undergo CAS
To assess the association between patient characteristics and outcomes, we compared the unadjusted 30-day mortality by quintile of propensity to undergo CAS. Figure 5 shows marked differences in survival by propensity quintile (PϽ0.0001). Patients least likely to undergo CAS (those in the 1st quintile) had a 30-day mortality of 0.49%, as compared with observed mortality rates of 1.51% and 1.01% in the highest 2 quintiles (probability value for trendϭ0.0006).
There was no significant interaction between treatment type and propensity quintile with mortality (Pϭ0.16), suggesting that the association between the probability of undergoing CAS and adverse outcome was independent of the method of revascularization, and more likely due to existing comorbidities.
Discussion Propensity Scoring and Stratification
In the emerging era of comparative effectiveness research, researchers will need to analyze observational studies to estimate the effects of different treatments in "real-world" practice. Because these researchers have no control over treatment assignment, there is an important risk of significant differences in covariates causing biased and imprecise estimates of treatment effects. Although marked progress in the statistical methodology to adjust for these imbalances has been made, including propensity-based and instrumental variable methods, rigorous assessment of the success of these methods to balance important covariates is needed. We used the largest available, clinically enriched database of patients being revascularized for significant carotid artery stenosis to describe the comparability of patients undergoing CAS or CEA procedures. We found that there was only modest clinical overlap for those patients least likely to be treated with CAS (the lowest 3 quintiles), and very poor clinical overlap in the upper 2 quintiles. Even after stratification by propensity score quintile, we found significant residual differences between the groups, including the prognostically important characteristics of ischemic heart disease, myocardial infarction within 6 weeks of revascularization, 16 and history or CAS/CEA restenosis. 17, 18 This challenges the direct comparison of these treatment groups. Moreover, we found an association between the likelihood of undergoing CAS and unadjusted 30-day mortality. Collectively, these findings call into question earlier reports comparing the outcomes of CAS and CEA 12 and underscore the challenges of comparative effectiveness studies in the management of carotid disease.
One approach to using observational data to compare the effectiveness of CEA and CAS in the treatment of carotid stenosis would be to restrict the analysis to those patients with sufficient covariate overlap. A recent report by Crump et al 19 describes an improved method of determining the optimal cutoff value to achieve a subpopulation that allows for the most precise estimation of the treatment effect. Applying this method to our sample, the optimal propensity score cutoff values in our cohort would be 0.12 to 0.88. This would remove roughly the entire 5th quintile, equating to 178 of the CEA and 2,324 of the CAS patients (one-third of the total CAS patients) before stratification and analysis of treatment effect. Moreover, the resultant analysis, which would exclude the patients with the greatest comorbidities, would have limited generalizability to clinical practice. Additionally, when so many measured differences are found between 2 groups (16 in the top 2 quintiles), it is likely that significant unmeasured differences also exist, further confounding attempts to compare the 2 groups. Unfortunately, randomized, controlled trials also tend to exclude similar patients with increased comorbidities, and novel strategies will be needed to conduct comparative effectiveness studies in the populations of patients treated with CAS in clinical care.
Guideline Adherence and Referral Bias
A great deal of the variation in the clinical characteristics of patients referred for CAS versus CEA probably can be explained by physician adherence to guidelines and recommendations regarding patient selection. In 2007, a multispecialty task force, which included members from the ACC, SCAI, SVM, SIR, and the Society of Interventional and Therapeutic Neuroradiology, published a consensus document on the clinical indications for CAS. 20 This 2007 Clinical Expert Consensus Document provides explicit criteria for categorizing patients as appropriate candidates for CAS. Appropriateness is based on a 3-level schema which includes symptoms, carotid stenosis severity, and the presence of Ն1 high-risk feature. Thus, adherence to these guidelines results in CAS being reserved for populations of patients with a considerably different set of clinical characteristics. Our study has affirmed that current referral patterns are in fact resulting in the expected disparity in clinical characteristics of patients referred for CAS and CEA. Regarding guideline adherence for carotid revascularization referral, a previous study from the CARE registry has shown that physicians are generally adherent to the expert recommendations, with 80% of all CAS procedures meeting all of the eligibility criteria established by this panel. 21 As physicians maintain proper adherence to specified referral guidelines, the significant clinical differences noted in our study are not only expected, but likely to continue, thus limiting the opportunity to conduct comparative effectiveness research across the spectrum of patients currently being treated with these procedures.
Future Directions for Registry Analysis
The analytic challenge of comparing groups with disparate clinical characteristics is not unique to the CARE registry. When attempting to measure clinically significant differences in outcomes between dissimilar groups, the careful selection of appropriate statistical methods is critical. Advanced techniques such as propensity scoring, polynomial regression modeling, and the use of instrumental variables will be vital to minimize biases inherent to large registries. It will be of equal importance to formulate clinically appropriate questions that can feasibly be answered by the data and methods available. Investigators will need to be aware that even with the use of sophisticated statistical methods, significant residual bias is likely to remain when comparing groups with extreme differences in baseline characteristics.
Limitations
Our findings should be interpreted in the context of the following potential limitations. This analysis was conducted within a large observational and voluntary registry. As a voluntary quality improvement registry, the 141 participating institutions may not be representative of CAS and CEA throughout the country. Furthermore, although there is standard and uniform data collection, with quality controls and participant feedback, there are likely to be many additional, prognostically important patient characteristics, such as detailed socioeconomic variables, health status, and depression, which were not collected and may also differ substantially between groups. Moreover, some important variables, such as noninvasive imaging data were made locally, without central core laboratory adjudication, and may introduce additional sources of potential confounding.
Conclusion
Many investigators have started comparing or are considering comparing the efficacy of CAS to CEA using data from observational studies. However, physician adherence to current guidelines regarding referral for these procedures has resulted in clinically and prognostically important differences in the clinical characteristics of patients treated with CAS or CEA. These extreme clinical differences suggest that conducting comparative effectiveness analyses of alternative treatment strategies for carotid revascularization will require large, clinically enriched data sets and sophisticated analytic methods to ensure that valid comparisons are made to guide future clinical practice, and that these comparisons are properly interpreted so that the limitations of these comparisons are transparently conveyed.
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CLINICAL PERSPECTIVE
In the emerging era of comparative effectiveness research, investigators will need to analyze data obtained from observational studies to estimate the effects of different treatments in "real-world" practice. Because researchers have no control over treatment assignment, there is an important risk of confounding by selection bias. Although advanced techniques such as propensity scoring are designed to minimize biases inherent to large registries, we found that, using a clinically enriched prospective registry, there are very large clinical differences between the populations of patients treated with carotid endarterectomy and carotid artery stenting. Among 8069 patients referred for carotid artery stenting and 4632 referred for carotid endarterectomy who were stratified across quintiles for the likelihood of undergoing carotid artery stenting, only 14% of patients in the upper 2 quintiles underwent carotid endarterectomy. Moreover, the mortality rate for these quintiles was substantially higher than the lower 3 quintiles (1.26% versus 0.59%, PϽ0.001). Without careful consideration of selection biases, which are particularly difficult to account for in administrative data, conducting comparative effectiveness research across treatments for carotid revascularization is likely to provide misleading results. 
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